TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemo… Read more
TriSalus Life Sciences Inc. (TLSI) - Total Assets
Latest total assets as of September 2025: $36.46 Million USD
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) holds total assets worth $36.46 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TriSalus Life Sciences Inc. - Total Assets Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TriSalus Life Sciences Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
TriSalus Life Sciences Inc.'s total assets of $36.46 Million consist of 86.2% current assets and 13.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.6% |
| Accounts Receivable | $5.09 Million | 21.2% |
| Inventory | $4.05 Million | 16.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how TriSalus Life Sciences Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TriSalus Life Sciences Inc.'s current assets represent 86.2% of total assets in 2024, a decrease from 92.9% in 2021.
- Cash Position: Cash and equivalents constituted 35.6% of total assets in 2024, down from 80.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 21.2% of total assets.
TriSalus Life Sciences Inc. Competitors by Total Assets
Key competitors of TriSalus Life Sciences Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
TriSalus Life Sciences Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - TriSalus Life Sciences Inc. generates 1.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TriSalus Life Sciences Inc. is currently not profitable relative to its asset base.
TriSalus Life Sciences Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.05 | 2.40 | 0.57 |
| Quick Ratio | 2.75 | 2.00 | 0.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.42 Million | $ 13.89 Million | $ -18.50K |
TriSalus Life Sciences Inc. - Advanced Valuation Insights
This section examines the relationship between TriSalus Life Sciences Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.29 |
| Latest Market Cap to Assets Ratio | 6.96 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | $23.97 Million |
| Market Capitalization | $166.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TriSalus Life Sciences Inc.'s assets at a significant premium ( 6.96x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: TriSalus Life Sciences Inc.'s assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for TriSalus Life Sciences Inc. (2021–2024)
The table below shows the annual total assets of TriSalus Life Sciences Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $23.97 Million | -2.55% |
| 2023-12-31 | $24.60 Million | +11.83% |
| 2022-12-31 | $22.00 Million | -41.87% |
| 2021-12-31 | $37.84 Million | -- |